ProCE Banner Activity

Evaluating and Managing High-Risk Disease in HR+/HER2- EBC (Without gBRCA)

Slideset

Get up to date on assessing risk and selecting among perioperative treatment options for patients with high-risk HR+/HER2- early breast cancer with wild-type BRCA status.

Released: June 01, 2023

Share

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC